A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk

Statistics in Medicine

Volumn 32, Issue 10, 2013, Pages 1763-1777

  Patel, Nitin R ^a,b   Ankolekar, Suresh ^c   Antonijevic, Zoran ^a   Rajicic, Natasa ^d  

^a Cytel Incorporated   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MAASTRICHT SCHOOL OF MANAGEMENT   (Netherlands)

^d PFIZER INC   (United States)

Author keywords

Budget constraints; Decision analysis; Phase 3 portfolio optimization; Portfolio re optimization; Risk; Stochastic integer programming

Indexed keywords

ARTICLE; BAYES THEOREM; BUDGET; DRUG APPROVAL; DRUG RESEARCH; FINANCIAL DEFICIT; LICENSING; MATHEMATICAL MODEL; PHASE 3 CLINICAL TRIAL (TOPIC); PROCESS OPTIMIZATION; RISK ASSESSMENT; SAMPLE SIZE; STOCHASTIC MODEL; STUDY DESIGN; UNCERTAINTY;

BAYES THEOREM; BIOSTATISTICS; BUDGETS; CLINICAL TRIALS, PHASE III AS TOPIC; DECISION SUPPORT TECHNIQUES; DRUG DISCOVERY; HUMANS; MODELS, STATISTICAL; RISK; STOCHASTIC PROCESSES;

EID: 84876441697     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5731     Document Type: Article

References (34)

1. Sarnes M. Drug discovery and development in a value-driven health care system. American Health and Drug Benefits 2009; 2(4):S164-S167.
2. Brigham EF, Houston JF. Fundamentals of Financial Management. South Western College Publications: Boston, MA, 2009.
3. Burman CF, Grieve AP, Senn S. Decision, analysis in drug development. In Pharmaceutical Statistics Using SAS®: A Practical Guide, Dmitrienko A, Chuang-Stein C, D'Agostino R (eds). SAS Institute, Cary, NC, 2007; 385-428.
4. Gatica G, Papageorgiou LG, Shah N. Capacity planning under uncertainty for the pharmaceutical industry. Chemical Engineering Research and Design 2003; 81(6):665-678.
5. Colvin M, Maravelias CT. A stochastic programming approach for clinical trial planning in new drug development. Computers & Chemical Engineering 2008; 32(11):2626-2642.
6. Colvin M, Maravelias CT. Scheduling of testing tasks and resource planning in new product development using stochastic programming. Computers & Chemical Engineering 2009; 33(5):964-976.
7. Jacob WF, Kwak YH. In search of innovative techniques to evaluate pharmaceutical R&D projects. Technovation 2003; 23:291-296.
8. Varma VA, Pekny JF, Blau GE, Reklaitis GV. A framework for addressing stochastic and combinatorial aspects of scheduling and resource allocation in pharmaceutical R&D pipelines. Computers and Chemical Engineering 2008; 32:1000-1015.
9. Rogers MJ, Gupta A, Maranas CD. Real options based analysis of optimal pharmaceutical research and development portfolios. Industrial & Engineering Chemistry Research 2002; 41:6607-6620.
10. Solak S, Clarke JPB, Johnson EL, Barnes ER. Optimization of R&D project portfolios under endogenous uncertainty. European Journal of Operational Research 2010; 207:420-433.
11. Blau GE, Rajan K, Pekny JF, Varma VA, Bunch PM. A genetic algorithm-based pharmaceutical portfolio selection and scheduling framework. Proceedings Foundations of Computer-aided Process Operations 2003 (FOCAPO2003), Coral Springs, Florida; 249-252.
12. Solo K, Paich M. A modern simulation approach for pharmaceutical portfolio management. International Conference on Health Sciences Simulation, San Diego, California. http://www.simnexus.com/SimNexus.PharmaPortfolio.pdf.
13. Patel NR, Ankolekar S. A Bayesian approach for incorporating economic factors in sample size and design for clinical trials and portfolios of drugs. Statistics in Medicine 2007; 26:4976-4988.
14. Aurentz V, Kirschbaum B, Thunecke M. Revitalizing portfolio decision-making at Merck Serono S.A.-Geneva. Journal of Commercial Biotechnology 2011; 17:24-36. DOI: 10.1057/jcb.2010.26.
15. Antonijevic Z, Pinheiro J, Fardipour P, Lewis RJ. Impact of dose selection strategies on the probability of success in phase III. Statistics in Biopharmaceutical Research 2010; 2(4):469-486.
16. Chen C, Beckman RA. Optimal cost-effective designs of phase II proof of concept trials and associated go-no go decisions. Journal of Biopharmaceutical Statistics 2009; 19:424-436.
17. Stallard N, Whitehead J, Cleall S. Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics 2005; 4:119-128. DOI: 10.1002/pst.164.
18. Willan AR, Pinto EM. The value of information and optimal clinical trial design. Statistics in Medicine 2005; 24:1791-1806. DOI: 10.1002/sim.2069.
19. Berry DA. Decision analysis and Bayesian methods in clinical trials. In Recent Advances in Clinical Trial Design and Analysis, Thall PF (ed.). Kluwer Academic Publishers: Boston, MA, 1995.
20. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science 2004; 19:175-187.
21. Gittin J, Pezeshk H. How large should a clinical trial be? The Statistician 2000; 49:1-14.
22. Hornberger JC, Brown BWM, Halpern J. Designing a cost-effective clinical trial. Statistics in Medicine 1995; 14:2249-2259.
23. Hornberger J, Eghtesady P. The cost-benefit of a randomized trial to a health care organization. Controlled Clinical Trials 1998; 19:198-211.
24. Julious SA, Swank DJ. Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. Pharmaceutical Statistics 2005; 4:37-46. DOI: 10.1002/pst.149.
25. Senn S. Some statistical issues in project prioritization in the pharmaceutical industry. Statistics in Medicine 1996; 15:2689-2702.
26. Zipfel A. Modeling the probability-cost-profitability architecture of portfolio management in the pharmaceutical industry. Drug Information Journal 2003; 37:185-205.
27. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Wiley: London, 2004.
28. O'Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4:187-201. DOI: 10.1002/pst.175.
29. Lee SJ, Zelen M. Clinical trials and sample size considerations: another perspective. Statistical Science 2000; 15:95-110.
30. Burman CF, Hamren B, Olsson P. Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics 2005; 4:47-58. DOI: 10.1002/pst.153.
31. Chow S, Shao J, Wang H. Sample Size Calculations in Clinical Research. Marcel Dekker: New York, 2003.
32. Birge JR, Louveaux F. Introduction to Stochastic Programming. Springer: New York, 2011.
33. Keeney RL, Raiffa H. Decisions with Multiple Objectives: Preferences and Value Tradeoffs. Wiley: New York, 1976.
34. Patel N, Bolognese J, Chuang-Stein C, Hewitt D, Gammaitoni A, Pinheiro J. Designing phase 2 trials based on program-level considerations: a case study of neuropathic pain. Drug Information Journal 2012; 46:439-454.